{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreigdfbvqp2pvhum7apkivqww6xa2jstvpzjwnegqrv5yjdndywmzoq",
    "uri": "at://did:plc:ox2kiwcr2xmn32p25g472pp7/app.bsky.feed.post/3mndlhydh3bc2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreia6okpsucro3byidsi3onzyrzvqfndkvtlaeqn55lulcbsgbzjmey"
    },
    "mimeType": "image/webp",
    "size": 78900
  },
  "path": "/releases/2026/06/260602021641.htm",
  "publishedAt": "2026-06-02T10:54:02.000Z",
  "site": "https://www.sciencedaily.com",
  "textContent": "A newly identified protein may be one of the biggest obstacles holding CAR T-cell therapy back. Researchers found that NFIL3 causes these engineered immune cells to become exhausted and lose their cancer-fighting power over time. When NFIL3 was disabled, the cells remained stronger for longer and controlled tumors more effectively in animal models.",
  "title": "A single protein may be holding back CAR T cancer therapy"
}